Steph & Co. Sells 3,009 Shares of Pfizer Inc. (NYSE:PFE)

Steph & Co. trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 25.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,672 shares of the biopharmaceutical company’s stock after selling 3,009 shares during the quarter. Steph & Co.’s holdings in Pfizer were worth $250,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Moneta Group Investment Advisors LLC boosted its position in shares of Pfizer by 89,592.7% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after purchasing an additional 160,963,976 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Pfizer by 10.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after purchasing an additional 9,393,992 shares in the last quarter. Morgan Stanley boosted its position in shares of Pfizer by 0.4% during the third quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock worth $2,817,055,000 after purchasing an additional 348,628 shares in the last quarter. Norges Bank acquired a new stake in shares of Pfizer during the fourth quarter worth $3,150,472,000. Finally, Massachusetts Financial Services Co. MA raised its holdings in shares of Pfizer by 9.4% during the third quarter. Massachusetts Financial Services Co. MA now owns 60,207,521 shares of the biopharmaceutical company’s stock worth $1,997,083,000 after acquiring an additional 5,185,453 shares during the period. 68.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently commented on PFE shares. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Monday. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a report on Thursday, January 4th. Finally, Guggenheim initiated coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Twelve investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $36.88.

Pfizer Stock Performance

PFE traded down $0.27 on Wednesday, reaching $25.42. The company had a trading volume of 43,603,051 shares, compared to its average volume of 42,571,469. Pfizer Inc. has a fifty-two week low of $25.26 and a fifty-two week high of $41.33. The stock has a market cap of $143.94 billion, a P/E ratio of 71.36, a P/E/G ratio of 1.18 and a beta of 0.61. The company’s fifty day moving average is $27.23 and its 200 day moving average is $28.79. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same quarter in the prior year, the business earned $1.14 EPS. Pfizer’s quarterly revenue was down 41.3% on a year-over-year basis. As a group, analysts predict that Pfizer Inc. will post 2.22 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.